NOVT — Novanta Inc.

Summary of Novanta Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $250 million, a 9% increase year-over-year, with 2% organic growth.
• Full Year 2025 Revenue: $981 million, marking a record year.
• Bookings: Increased by 25% year-over-year and 12% sequentially, with a book-to-bill ratio of 1.11.
• Adjusted EBITDA: $61 million in Q4, up 17% year-over-year, with a margin of 23.5%.
• Adjusted EPS: $0.91 for Q4, a 20% increase year-over-year; full year adjusted EPS was $3.29, up 7%.
• Operating Cash Flow: $9 million in Q4, down from $62 million in Q4 2024; full year cash flow was $64 million.
• Gross Margin: Q4 adjusted gross margin was 45.5%, down from 47% in Q4 2024.

2. Strategic Updates and Business Highlights

• Growth Strategy: Focus on high-growth markets such as AI-driven robotics, minimally invasive surgery, and precision medicine.
• Product Innovation: New product sales grew over 80% year-over-year in Q4, contributing to a vitality index of 24% of total sales.
• Acquisition Pipeline: Raised $600 million in November to support acquisitions, with nearly $1.5 billion in total acquisition capacity.
• Market Performance: Strong growth in advanced surgery (15% growth), robotics and automation (6% growth), and precision manufacturing (sequential growth of 8%).

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected GAAP revenue of $1,030 million to $1,050 million, representing 4% to 6% organic growth.
• Q1 2026 Guidance: Anticipated revenue of $250 million to $255 million, with organic growth of 1% to 3%.
• Gross Margin Target: Expected to improve to approximately 47% for 2026, with a sequential increase in Q1.
• Operating Cash Flow Guidance: Projected to rebound to $145 million to $185 million for 2026.

4. Bad News, Challenges, or Points of Concern

• Margin Compression: Q4 margins declined due to prioritizing customer deliveries over manufacturing transfers, leading to higher costs and inventory levels.
• Cash Flow Decline: Significant drop in operating cash flow in Q4 compared to the previous year, attributed to regional manufacturing dynamics and inventory buildup.
• Dilution from Fundraising: The equity fundraise is expected to impact EPS growth by $0.22 to $0.24 due to increased share count.

5. Notable Q&A Insights

• Bookings Dynamics: All business units reported double-digit bookings growth, with strong momentum in robotics and automation driven by AI applications and semiconductor market recovery.
• Keyon Acquisition: Contributed $9 million in incremental revenue in Q1 2026, exceeding initial expectations and showing promise for future growth.
• Competitive Positioning: Novanta is positioned as a leader in precision robotics and AI applications, with strong relationships with OEMs, which are expected to drive future growth.
• Market Trends: The company is observing a shift towards digital and AI-enabled manufacturing, which aligns with its strategic focus on innovation and customer needs.

Overall, Novanta Inc. demonstrated strong performance in Q4 2025, with significant growth in bookings and revenue, although challenges related to margins and cash flow were noted. The outlook for 2026 remains positive, with expectations for continued growth driven by strategic investments and acquisitions.